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Background: Debate about the potential effects that surgery might have on cancer cells dormancy and
angiogenesis prompted us to investigate the impact of breast surgery on circulating angiogenesis modulating gene
transcripts and proteins.
Methods: Blood samples from 10 female patients diagnosed with breast cancer and 6 with fibroadenoma were
collected before surgery and post-operatively on days 3 and 7 (breast cancer patients only). A set of 84
angiogenesis-associated transcripts were assessed using quantitative PCR arrays, and circulating protein levels
(vascular endothelial growth factor A (VEGFA), IL8 and fibroblast growth factor 2 (FGF2) were measured using ELISA
in the same samples. The results were investigated against clinicopathological data and patient outcome.
Results: Plasma levels of VEGFA and IL8 after surgery were significantly elevated in the breast cancer group
compared to the control group (P = 0.038 and P = 0.021, respectively). In the cohort of breast cancer patients,
VEGFA increased on day 3 (P = 0.038) and declined on day 7 (P= 0.017), while IL8 did not change on day 3 but
showed a significant decline on day 7 (P = 0.02). FGF2 levels did not change significantly over time. Regarding
gene transcripts, we detected upregulation of a significant number of angiogenesis-specific genes in patients with
breast cancer versus controls: sphingosine kinase 1(SPHK1), epidermal growth factor (EGF), vascular endothelial
growth factor C (VEGFC), neuropilin 1 (NRP1), fibroblast growth factor (FGF1), laminin alpha 5 (LAMA5), collagen
type IV alpha 3 (COL4A3), IL8, ephrin B2 (EFNB2), ephrin A3 (EFNA3), tyrosine endothelial kinase (TEK), integrin beta
3 (ITGB3), AKT1, thrombospondin 1 (THBS1), chemokine (C-C motif) ligand 11 (CCL11) and TIMP metallopeptidase
inhibitor 3 (TIMP3). Surgery induced an altered expression in several keygenes in breast cancer patients. We
identified an upregulation of COL4A3 and downregulation of chemokine (C-X-C motif) ligand 9 (CXCL9), EGF, FGF1,
Kinase insert domain receptor (KDR), Placental growth factor (PGF), TIMP3 and VEGFC.
Conclusion: Breast cancer patients have a different expression profile of circulating angiogenesis biomarkers
compared to patients with fibroadenoma. Moreover, mastectomy promotes a transient increase of VEGFA and a
shift in the expression patterns of a broad panel of angiogenesis-related circulating gene transcripts.
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37 (range, 28–47) 55 (range, 36–76)
Disease Fibroadenoma Invasive ductal
carcinoma
Disease site
Right breast 3/6 8/10
Left breast 3/6 2/10
Surgical procedure
WLE 6/6 -
WLE + ALND - 5/10



















Blood samples PRE, day 3 PRE, day 3, day 7
ALND axillary lymph node dissection, ER estrogen receptors, MRM modified
radical mastectomy, PR progesterone receptors, PRE day before surgery, WLE
wide local excision.
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Surgery is the cornerstone of therapy for early breast
cancer. Resection of the primary tumor and axillary lymph
nodes in the absence of distant metastases has always
been considered curative for non-metastatic disease. How-
ever, development of distant metastases within the first
few years after tumor resection challenges this notion to
some extent [1,2]. A number of experimental and clinical
studies have suggested that, although surgical resection of
breast cancer has beneficial effects for the majority of
patients, it might also trigger cancer spread and growth
in some others [3,4].
It is now known that breast cancer, even in the early
stages, is systematically spread in one-third of the
patients already with a diagnosis [5]. It is therefore
thought that surgery might affect cancer cell dormancy
and trigger angiogenesis [6-9]. Currently, several studies
have focused on angiogenesis in breast cancer [10,11]
but only a few have investigated the kinetics of the best
known circulating pro-angiogenic molecules in blood or
fluid from wound drains and their expression in cancer
tissue [12-15].
We studied the expression of a set of 84 circulating
angiogenesis-regulating gene transcripts and key pro-
teins in patients with breast cancer and evaluated their
expression pattern and kinetics following mastectomy
for potential clinical relevance.
Methods
Patients
Ten breast cancer patients and six patients with fibro-
adenoma were enrolled in this study. The Institutional
Review Board of the University of Ioannina approved
the study protocol. Inclusion criteria were scheduled
surgery for operable early breast cancer or benign tumor
and patient consent. Exclusion criteria were the follo-
wing: diabetes mellitus, active inflammation during the
peri-operative period, recent myocardial infarction, peri-
operative blood transfusion, erythropoietin administration,
and synchronous malignancies because of potential inter-
ference with angiogenesis [16]. A signed informed consent
was obtained from all participating in the study patients.
Patient demographics are shown in Table 1. The six
patients with benign breast disease initially underwent
an excisional biopsy in macroscopically healthy borders
due to suspicious mammographic findings. If frozen
section microscopy excluded cancer, a suction drain was
placed and the operation terminated. All breast cancer
patients had a core-biopsy performed prior to surgery.
The type of procedure (modified radical mastectomy or
wide local excision) was decided prior to surgery, follo-
wing surgeon consultation and considering the patient’s
desire. The same experienced Senior Surgeon who leads
the Breast Unit performed all surgical procedures. Astandard protocol of general anesthesia was applied
to all cases, using Propofol–Fentanyl–muscle relaxant
induction and O2–Sevoflurane maintenance. Histo-
pathologic examination of specimens was done by a
single pathologist who specializes in breast tissue
biopsies and immunohistochemistry. Patients with
positive axillary lymph nodes received adjuvant the-
rapy according to tumor biology, while those that




















Figure 1 Aligned plot of repeated measures of vascular
endothelial growth factor A (VEGFA) with matched values
stacked in subcolumns. The outlier refers to a patient with locally
advanced disease (T2N2) who eventually relapsed.
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Blood was drawn via venipuncture by the same person
every time, using a 21G BD Vacutainer® Safety-Lok™
Blood Collection Set (BD Diagnostics, Franklin Lakes
NJ, USA). For each patient with breast cancer, three
blood collections were undertaken at the following time
intervals: on the day before surgery and on postopera-
tive days 3 and 7. Patients with fibroadenoma had their
blood samples collected preoperatively and on day 3
after surgery. All samples were collected in the morn-
ing (between 8 and 10 am) and at room temperature.
Each blood collection consisted of two PAXgene™
Blood RNA tubes (PreAnalytix, GmbH, Hombrechtikon,
Switzerland), containing 2.5ml whole blood each (plus
6.9 ml RNA stabilization reagent) and four plasma
BD Vacutainer® tubes (BD Diagnostics), containing
2ml whole blood (together with K2ethylenedia-
minetetraacetic acid (EDTA) at a concentration of
3.6mg/ml).
PAXgene™ Blood RNA tubes were carefully incubated 8
to 10 times for appropriate mixing with the reagent and
then placed in the upright position at room temperature
for at least 2 hours (according to the manufacturer’s
suggestions), before being finally stored at −80°C.
Plasma samples were centrifuged for 15 minutes at 3,000
rpm (at room temperature) within 30 minutes of the col-
lection time. The supernatant was collected with a pipette
and placed in Eppendorf® (Eppendorf-Netheler-Hinz,
GmbH, Hamburg, Germany) tubes before freezing at
−80°C. All samples were stored frozen at the Univer-
sity of Ioannina Cancer Biobank Center. Collection of
all of the samples had been completed within a period
of 2 months.
RNA isolation
For RNA extraction, the PAXgene blood RNA extraction
kit (PreAnalytix, GmbH) was used according to the
manufacturer’s instructions. RNA integrity was checked
by RNA electrophoresis. Only RNAs with RNA integrity
number >7 were used for reverse transcription and
further processing. Purified RNA samples were then
subjected to quantitative analysis, using the NanoDrop®
ND-1000 spectophotometer (Thermo Fisher Scientific®,
Wilmington, DE, USA), with measurements in a range
of 230 to 350 nm. A260/A280 values were about 2 for all
samples, indicating highly purified RNA. Qualitative ana-
lysis was performed with RNA gel electrophoresis 1.2%.
For reverse transcription, the SABiosciences RT2 First
Strand kit was used (SABiosciences/Qiagen, Frederick,
MA, USA). In all cases 0.5 μg RNA were reversed tran-
scribed. Simultaneous quantification of 84 gene tran-
scripts involved in angiogenesis was performedusing the
angiogenesis RT2 profiler PCR Array (PAHS-024F,
SABiosciences/Qiagen). Relative expression was determinedwith the LightCycler® 480 instrument (Roche, Rotkreuz,
Switzerland) and the ΔΔCt method [17].
Vascular endothelial growth factor A, fibroblast growth
factor 2 and interleukin 8 protein measurements
EDTA plasma samples were analyzed using commercial
ELISA kits for vascular endothelial growth factor A
(VEGFA), fibroblast growth factor 2 (FGF2) and CXCL8/
IL8 (R&D Systems Inc, Quantikine, Minneapolis, MN,
USA). Aliquots of 100 μl were used for VEGFA and FGF2
and 50 μl for IL8 analysis. All analyses and calibrations
were carried out in duplicate. The calibration on each
microplate used recombinant VEGFA, FGF2 and IL8
standards, respectively. Optical densities were determined
using a microplate reader at 450 nm. The blank was
subtracted from the duplicate readings for each standard
and sample. A standard curve was created by plotting the
logarithm of the mean absorbance of each standard versus
the logarithm of the VEGFA, FGF2 and IL8 concen-
trations. VEGFA, FGF2 and IL8 concentrations are
reported as pg/ml. The sensitivity of the assay for
VEGFA is 9 pg/ml with a detection range of 31.2 to
2,000 pg/ml. The ELISA kit for CXCL8/IL8 has a sensi-
tivity of 1.5 to 7.5 pg/ml and the reliable standard curve
ranges from 31.2 to 2,000 pg/ml. The Quantikine®
Human FGF2 immunoassay kit has a minimum detec-
table dose less than 3 pg/ml with a detection range of
10 to 640 pg/ml.
Patient outcome
All patients were assessed for local recurrence or
development of metastatic disease according to stan-
dard follow-up protocols. Duration of follow-up
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During follow-up none of the patients died but one
patient (aged 58 years) who had undergone a wide
local excision due to a T2N2 invasive ductal carci-
noma was re-operated because of local recurrence in
the axilla 3 years later.Statistical analysis
Paired and unpaired t tests were performed using
GraphPad Prism version 6.00 for Mac OS X (GraphPad
Software, La Jolla, CA, USA; www.graphpad.com). Dif-
ferences with P< 0.05 were considered statistically
significant.Figure 2 Circulating vascular endothelial growth factor A (VEGFA), fib
different time points before and after surgery. (A) Both groups of patie
D3,sampling on postoperative day 3; D7,sampling on postoperative day 7.Results
Plasma levels of circulating pro-angiogenic factors
Firstly, we measured plasma levels of VEGFA, IL8 and
FGF2, three of the most significant pro-angiogenic
factors.
Regarding VEGFA, non-cancer subjects had values
ranging between 10 and 36.9 pg/ml preoperatively
(mean, 21.145 pg/ml), in contrast to breast cancer pa-
tients who showed values between 18 and 108.54 pg/ml
(mean, 48.17 pg/ml), a difference which proved to be sta-
tistically significant (P = 0.038). In the group of breast
cancer patients, VEGFA initially increased in all patients
and declined back on day 7, except for one outlier with
locally advanced disease (T2N2) who eventually relapsedroblast growth factor 2 (FGF2) and IL8 levels measured at
nts. (B) Breast cancer patients only. Values are shown as means± SEM.







SPHK1 Sphingosine kinase 1 12.196
EGF Epidermal growth factor 5.8563
VEGFC Vascular Endothelial Growth Factor-C 4.9417
NRP1 Neuropilin 1 2.9214
FGF1 Fibroblast growth factor 2.8712
LAMA5 Laminin, alpha 5 2.2842




TEK TEK tyrosine kinase, endothelial 2.835
ITGB3
Integrin, beta 3 (platelet glycoprotein IIIa, antigen 
CD61) 2.7195
AKT1 V-akt murine thymoma viral oncogene homolog 1 2.2372
THBS1 Thrombospondin 1 2.2064
CCL11 Chemokine (C-C motif) ligand 11 2.1785
TIMP3 TIMP metallopeptidase inhibitor 3 2
GENES DOWN-REGULATED
CXCL10 Chemokine (C-X-C motif) ligand 10 -2.0139
Figure 3 Scatter plot analysis and heat map of all patient samples preoperatively. The heat map demonstrates comparative expression of
all 84 genes. Significantly upregulated genes (for example, SPHK1) are depicted in a more intense red color (F09), while significantly
downregulated genes are shown with a more intense green color (for example, CXCL10 in B02). The graph below plots the log10 of normalized
gene expression levels between the control group (x-axis) and the breast cancer group (y-axis). Genes with a more than twofold upregulation in
the breast cancer group are depicted in the upper left corner with red dots, while genes which are more than twofold downregulated are
represented in the lower right section with green dots (these genes are analytically listed in the adjacent table).
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cance on day 3 compared to presurgical values and on
day 7 compared to day 3 (P =0.038 and 0.017, respec-
tively; Figure 2B).
FGF2 values were quite similar for both the control
and the study group preoperatively and in some cases
below the detection limit of the assay. A postsurgical
increase was documented in most patients. This in-
crease continued on day 7 following surgery for the
breast cancer group. However, these changes did not
reach statistical significance at any time point
(Figure 2).
IL8 expression was higher in the study group prior
to surgery, with values ranging between 2.59 and
33.7 pg/ml (mean, 16.33 pg/ml), a difference that was
statistically significant (P = 0.021). In breast cancerpatients, IL8 initially showed a slight increase towards day
3, but on day 7 it decreased to levels lower than the
preoperative values (P = 0.02) (Figure 2).Gene expression analysis
We performed quantitative RT-PCR analysis for 84
angiogenesis related genes in blood from patients with
breast cancer and fibroadenoma before surgery. A
scatter-plot analysis of the results together with a heat
map is shown in Figure 3, as well as a comprehensive
list of all the changes.
We also analyzed the expression of gene transcripts
between patients with cancer and benign breast disease
after surgery in an effort to identify possible differences






SPHK1 Sphingosine kinase 1 4.9189
COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) 4.6536
BAI1 Brain-specific angiogenesis inhibitor 1 2.0023





SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 1
-2.4256
CXCL9 Chemokine (C-X-C motif) ligand 9 -4.8568
CXCL10 Chemokine (C-X-C motif) ligand 10 -4.4898
IL1B Interleukin 1, beta -2.6147
CCL2 Chemokine (C-C motif) ligand 2 -2.4425
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha)
-2.3161
HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor)
-2.3001
NOTCH4 Notch 4 -2.0023
Figure 4 Scatter plot analysis and heat map of all patient samples on postoperative day 3. Significantly upregulated genes (for example,
SPHK1) are depicted in a more intense red color (F09), while significantly downregulated genes are shown with a more intense green color (for
example, CXCL10 in B02). The graph below plots the log10 of normalized gene expression levels between the control group (x-axis) and the
breast cancer group (y-axis). Genes with a more than twofold upregulation in the breast cancer group are depicted in the upper left corner with
red dots, while genes which are more than twofold downregulated are represented in the lower right section with green dots (these genes are
analytically listed in the adjacent table).
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sults are shown in Figure 4.
Surgery induced an altered expression in several
keygenes in breast cancer patients. We identified an
upregulation of SPHK1, COL4A3, BAI1 and ITGB3,
and downregulation of EREG, SERPINF1, CXCL9,
CXCL10, IL1B, CCL2, CXCL1, HIF1A and NOTCH4.Postoperative kinetics of angiogenesis-related genes in
breast cancer (postoperative day 3 to day 7)
Analysis of changes in gene expression between post-
operative days 3 and 7 revealed overexpression of several
circulating transcripts which were previously under-
expressed. Moreover, COL4A3, which was initially
upregulated, showed significant downregulation bet-
ween days 3 and 7. CXCL9, FGF1 and TIMP3 seem to
show an opposite trend.Discussion
We investigated the impact of mastectomy for breast
cancer on circulating molecules of angiogenesis. For this
purpose, serial blood measurements were obtained from
10 cancer patients who underwent mastectomy before
and up to postsugery day 7, and 6 patients with fibro-
adenoma who served as a control group.
VEGFA is a key player in the process of angiogenesis
[18]. Several studies have tried to link circulating VEGFA
with disease stage and prognosis [19]. In our study, pre-
operative levels of this angiogenic factor were found
significantly higher in the breast cancer group compared
to the control group. Postoperatively, a transient in-
crease in circulating levels of VEGFA was documented
for nearly all patients who underwent surgery for breast
cancer 3 days after surgery which waned back 4 days
later. FGF2 is another major proangiogenic cytokine
[20]. We found a trend towards increased levels in
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[15]. Finally, IL8 increased only marginally after surgery
on day 3 but settled down to values near the detection
limit 1 week postsurgery.
We also analyzed perioperative kinetics of circulating
transcripts of angiogenesis-related genes to profile gene
expression patterns. We first compared the results from
the samples that were obtained preoperatively in both
the control group and the cancer group. We found
upregulation of a significant number of angiogenesis-
specific genes in breast cancer patients compared with
controls: sphingosine kinase 1 (SPHK1), epidermal
growth factor (EGF), vascular endothelial growth fac-
tor C (VEGFC), neuropilin 1 (NRP1), fibroblast growth
factor (FGF1), laminin alpha 5 (LAMA5), collagen type
IV alpha 3 (COL4A3), IL8, ephrin B2 (EFNB2), EFNA3,
tyrosine endothelial kinase (TEK), integrin beta 3
(ITGB3), V-akt murine thymoma viral oncogene homolog
1 (AKT1), thrombospondin 1 (THBS1), chemokine (C-C
motif) ligand 11 (CCL11) and TIMP metallopeptidase
inhibitor 3 (TIMP3). This finding can be explained by
the fact that, even at early-stages of disease, the process
of angiogenesis has already prompted upregulation of
certain proangiogenic factors.
Some of the identified factors have an established role
in the process of angiogenesis. EGF is overexpressed in
triple-negative breast cancer [21] and has a synergic role
to the induction of angiogenesis by VEGF [22]. VEGFC
binds to its receptor VEGFR3 and promotes lymphatic
hyperplasia and lymphangiogenesis [13,23,24]. FGF1 has
also been shown to possess proangiogenic properties
[12,25] and IL8 is another established proangiogenic
cytokine [26,27]. However, the greatest amplification of
genes was seen with SPHK1, EGF and VEGFC. SPHK1
is one of two (together with SPHK2) generating enzymes
of sphingosine-1-phosphate (S1P), which is an active
sphingolipid metabolite. During the last decade, several
studies have revealed the emerging role of S1P as a key
molecule in human cancer development [28], angio-
genesis and lymphangiogenesis [29]. Overexpression of
SPHK1 in tumors [30] is now believed to be the result of
hypoxia and HIF1α induction [31]. Moreover, SPHK1
has been shown to have a prognostic significance in breast
cancer [32]. On the other hand, CXCL10 (also named
IP-10), which is a member of the CXC chemokine family
with potent antiangiogenic properties, was found to be
downregulated in breast cancer patients [33-35].
We also sought to determine the effect of surgery
upon the process of angiogenesis by comparing any pos-
sible alterations in specific gene expression between the
two groups of patients on postoperative day 3. SPHK1,
COL4A3, BAI1 and ITGB3 demonstrated a significant
upregulation, while a number of other factors (mostly
chemokines) were downregulated (Figure 4). SPHK1,COL4A3 and ITGB3 continue to be upregulated, as they
were preoperatively. Apart from these genes, brain-
specific angiogenesis inhibitor 1 (BAI1) also displays an
augmented expression. BAI1 is a factor that has been
mostly studied in the context of brain tumors, but it
may well possess antiangiogenic effects upon other
malignancies [36]. On the other hand, a hard to explain
downregulation was seen for certain circulating angio-
genesis promoters, such as HIF1, NOTCH and CXCL9.
Finally, we analyzed longitudinal recordings of tran-
script expression data in breast cancer patients that
focused on three time points: preoperative, and days 3
and 7 postoperatively. We detect an initial upregulation
for COL4A3 on day 3, followed by a later down-
regulation towards day 7. The opposite trend was shown
for CXCL9, FGF-1 and TIMP-3.
Conclusions
The results of this study demonstrate that breast
cancer patients have a different expression profile of
angiogenesis-related factors when compared to pa-
tients with benign breast diseases. Moreover, we found
that surgical wounding might influence the process of
angiogenesis in the context of wound healing, de-
monstrating for the first time that a broad panel of
angiogenesis-related genes shift expression patterns
after surgery. A more thorough study of gene profiling
could possibly offer new insights for the establishment
of specific biomarkers with prognostic significance in
breast cancer and potential implications in decisions
regarding postsurgical adjuvant therapy.
Consent
Written informed consent was obtained from all the
patients for the publication of this report and any ac-
companying images.
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